Immune-checkpoint blockade of CTLA-4 (CD152) in antigen-specific human T-cell responses differs profoundly between neonates, children, and adults

The monoclonal antibody against CTLA-4, Ipilimumab, is a first-in-class immune-checkpoint inhibitor approved for treatment of advanced melanoma in adults but not extensively studied in children. In light of the fact that the immune response early in life differs from that of adults, we have applied...

Descripción completa

Detalles Bibliográficos
Autores principales: Arra, Aditya, Pech, Maximilian, Fu, Hang, Lingel, Holger, Braun, Franziska, Beyer, Christian, Spiliopoulou, Myra, Bröker, Barbara M., Lampe, Karen, Arens, Christoph, Vogel, Katrin, Pierau, Mandy, Brunner-Weinzierl, Monika C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204976/
https://www.ncbi.nlm.nih.gov/pubmed/34178430
http://dx.doi.org/10.1080/2162402X.2021.1938475

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8204976/
https://www.ncbi.nlm.nih.gov/pubmed/34178430
http://dx.doi.org/10.1080/2162402X.2021.1938475

Ejemplares similares